NCT07457528招募中2 期
Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2026年3月12日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- MPR
研究概览
简要总结
This trial is conducted in patients with resectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 46 patients with resectable locally advanced esophageal cancer in Tianjin cancer hospital. Patients will be treated with serplulimab, nimotuzumab plus concurrent chemoradiotherapy (41.4Gy/1.8Gy/23F) . Six to eight weeks after the completion of neoadjuvant chemoradiotherapy, patients who are considered operable by surgeons will undergo radical resection of esophageal cancer. Postoperative pathological assessment includes MPR rate, pCR rate, and pathological response grade, etc. This trial aims to explore the safety and efficacy of adding serplulimab and nimotuzumab to neoadjuvant chemoradiotherapy, with a focus on whether the combined treatment regimen can enhance the efficacy and safety of neoadjuvant chemoradiotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign an informed consent form.
- •Age ≥ 18 years, ≤ 75 years, both genders are eligible.
- •Patients with histologically confirmed clinical stage of locally advanced (cT1N2-3M0 or cT2-4aN0-3M0) thoracic esophageal squamous cell carcinoma (8th UICC-TNM staging).
- •Expected to achieve R0 resection.
- •No prior treatment for the primary esophageal tumor, including drug therapy, surgery, and radiotherapy.
- •No suspicious metastatic lymph nodes in the neck as suggested by neck enhanced CT or neck ultrasound; no systemic metastasis on imaging studies.
- •Measurable lesions according to RECIST 1.1 criteria.
- •Important organ functions meet the following requirements:
- •Absolute neutrophil count ≥ 1.5×10^9, platelets ≥ 80×10^9, hemoglobin ≥ 90g/L;
- •Total bilirubin level ≤ 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times ULN (for patients with liver metastasis, AST and ALT levels ≤ 5 times ULN);
- •Serum creatinine ≤ 1.5 times ULN or creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula);
- •Serum albumin ≥ 28g/L;
- •Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%);
- •Pulmonary function: FEV1/FVC ≥ 70%, FEV1 ≥ 50% of normal value, DLCO (diffusing capacity of the lung for carbon monoxide) measured value to predicted value percentage > 80%.
- •Women of childbearing age must agree to use contraception (such as intrauterine device, contraceptive pills, or condoms) during the study and for 6 months after the study ends; negative serum or urine pregnancy test within 7 days before study enrollment, and must be non-lactating patients; men must agree to use contraception during the study and for 6 months after the study ends.
- •Must understand and sign the informed consent form.
排除标准
- •Within the past six months, received EGFR monoclonal antibodies or EGFR-TKIs.
- •Participated in other interventional clinical trials within 30 days prior to screening.
- •Have severe comorbidities, such as heart failure, high-risk uncontrollable arrhythmias, severe myocardial infarction, refractory hypertension, renal failure (CKD stage 4 or higher), thyroid dysfunction, mental disorders, diabetes, severe chronic diarrhea (more than 7 bowel movements per day), etc., and those deemed unsuitable for this clinical study by the investigator.
- •Patients with brain metastases with symptoms or symptom control for less than 3 months.
- •History of other malignancies (except for cured in situ cervical cancer or skin basal cell carcinoma, and other malignancies cured for more than 5 years).
- •Presence of active infection or active infectious disease.
- •Multifocal esophageal malignant tumors or presence of esophageal fistula or perforation signs.
- •Imaging shows tumor invasion of important blood vessels, or the investigator determines that the tumor is highly likely to invade important blood vessels during the subsequent study period, leading to fatal major bleeding.
- •Allergy to the drugs used in this protocol or their components.
- •According to the Common Terminology Criteria for Adverse Events (NCI CTCAE V5.0), peripheral neuropathy or hearing loss of grade ≥
- •Pregnant or breastfeeding women.
- •Those with a history of psychiatric drug abuse and unable to quit, or patients with mental disorders.
- •Those deemed unsuitable for this study by the investigator.
- •Those unwilling to participate in this study or unable to sign the informed consent form.
研究组 & 干预措施
Serplulimab+Nimotuzumab+Chemoradiation
Experimental
干预措施: HLX10 (Drug)
Serplulimab+Nimotuzumab+Chemoradiation
Experimental
干预措施: Chemotherapy (Drug)
Serplulimab+Nimotuzumab+Chemoradiation
Experimental
干预措施: Nimotuzumab (Drug)
结局指标
主要结局
MPR
时间窗: 3 months after the last subject participating in
Major Pathological response
次要结局
- pCR(3 months after the last subject participating in)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCCNCT07403136Fudan University104
尚未招募
2 期
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCCNCT07403435Union Hospital, Tongji Medical College, Huazhong University of Science and Technology22
招募中
1 期
MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell CarcinomaNCT07359417UMC Utrecht30
尚未招募
3 期
A major study is testing two treatments for esophageal cancer that can still be removed with surgery. One group gets three chemo drugs before surgery, while the other gets the same chemo plus an immune-boosting treatment. The goal is to see which shrinks tumors better and improves patient outcomesCTRI/2025/02/080989Tata Memorial Centre362
招募中
2 期
Testing a New Treatment Combining Chemotherapy and Radiation Before Surgery for Advanced Triple-Negative Breast CancerCTRI/2025/01/079814NOT APPLICABLE44